Objective: The aim of the study was to assess the ability of contrastenhanced computed tomography (CECT) to differentiate aggressive from nonaggressive solid pseudopapillary neoplasms (SPNs).
S
olid pseudopapillary neoplasms (SPNs) account for 1% to 2% 1,2 of pancreatic neoplasms, and approximately 50% of SPNs are detected incidentally. Since the late 1950s, SPN of the pancreas has been recognized as a separate entity among pancreatic neoplasms. 1, 3 Solid pseudopapillary neoplasms are most commonly seen in young females often in their 20s but can also be seen in patients ranging in age of 2 to 85 years. 2 Solid pseudopapillary neoplasms are generally thought to be low-grade neoplasms with an indolent growth pattern regardless of the presence of metastatic disease. The originating cell of these tumors in the pancreas is unclear. Theories include origination from acinar and endocrine cells, centroacinar cells, or possibly genital ridge-related cells. [4] [5] [6] [7] [8] Most SPNs activate the Wnt-signaling pathway 9 and have somatic point mutations in exon 3 of CTNNB1. This mutation results in focal abnormal nuclear localization of the β-catenin protein, which can be visualized on immunohistochemical analysis. Typically, the neoplastic cells in SPN are uniform polyhedral cells with grooved nuclei, loosely arranged around delicate fibrovascular cores. This pattern is fairly uniform despite heterogeneity in morphologic patterns, with solid, pseudopapillary, or microcystic pattern. 10 In 1990, Matsunou et al 11 reported invasion of surrounding pancreatic parenchyma on microscopy along with cellular atypia in case reports of SPNs. They also found a higher degree of malignant change in long-standing tumors.
Solid pseudopapillary neoplasms have an abnormal nuclear position of β-catenin, detected by immunohistochemical analysis. 4 These tumors express vimentin, CD10, and neuron-specific enolase and demonstrate a loss of E-cadherin from the cytoplasmic membrane. 12 However, no specific pathologic marker has been linked to the malignant potential of this tumor. 13 Characteristics associated with malignant potential or "aggressive behavior" (metastatic disease or recurrence) on histologic analysis include extrapancreatic invasion, pancreatic parenchymal invasion, and perineural 14 or vascular (especially muscular vessels) wall invasion. 15, 16 Nuclear pleomorphism alone has not been found to be related to aggressiveness in these tumors 10, 17 ; however, the presence of undifferentiated carcinoma in rare cases has a particularly aggressive course. High Ki-67 immunoreactivity has been suggested to be related to poor outcomes in SPNs. 18, 19 Solid pseudopapillary neoplasms have a different etiology and pathogenesis from pancreatic ductal cancer and neuroendocrine tumors and may require their own markers for determining prognosis. 20 Radiologic features that have been suggested to predict SPN aggressiveness on imaging include tumor size, soft tissue component within the tumor, 21 focal discontinuity or invasion of the capsule, 21 and lobulated margins. [22] [23] [24] The aim of our study was to retrospectively evaluate the utility of contrast-enhanced computed tomography (CECT) in differentiation of aggressive from nonaggressive SPNs.
MATERIALS AND METHODS
This retrospective, single-institution, institutional review boardapproved study included patients with pathologically proven pancreatic SPNs. Patients with SPNs were identified by a search of the radiology database. Patients who had surgical resection before assessment at our institution were excluded. A total of 40 treatment-naive patients with pathologically proven SPNs were included in the study. Patients without arterial and portal venous phase CECT imaging as well as patients who did not have a pancreatic protocol with a noncontrast study were excluded from the final analysis. Thirty-five patients had noncontrast, arterial, and portal venous phase examinations. Four patients did not have precontrast and arterial phase imaging performed. Only 30 of these patients had delayed phase imaging. Imaging characteristics were determined by the consensus of 3 radiologists who were blinded to the final histopathologic status with respect to tumor aggressiveness and whose experience in radiology totaled 4 years (V.S.), 15 years (P.B.), and 17 years (K.E.).
Imaging Protocol
The CECT examinations were performed on a 64-detector computed tomography scanner (LightSpeed VCT; GE Healthcare, Milwaukee, WI). The pancreatic parenchymal scanning was performed at a 2.5-mm slice thickness (revolution time = 0.5 seconds, pitch = 0.5:1, table feed/rotation = 20.625 mm, 120 kVp and mA was automated based on field of view) using smart prep (GE Healthcare, Milwaukee, WI) with a monitoring delay of 10 seconds, an aortic enhancement threshold of 100 Hounsfield units (HU), and a diagnostic delay of 20 seconds after administration of 125 mL of intravenous contrast (Omnipaque 300; GE Healthcare, Cork, Ireland) at 4 mL/s, and was preceded by noncontrast study through the abdomen. The portal venous phase scan was performed 20 seconds after the arterial phase scan, and the delayed phase scan was performed 15 seconds after the portal venous phase scan. Multiplanar reconstructions were performed in the sagittal and coronal planes.
Qualitative Analysis
The SPNs were analyzed for imaging features of size, location, wall thickness (imperceptible vs perceptible), shape (irregular, lobulated, or round), margins (well-circumscribed vs poorly circumscribed), gross vascular invasion, and associated pancreatic or common bile duct dilation. The largest size of the tumor was recorded in the axial, coronal, or the sagittal plane (see Figures, Supplemental Digital Content, http://links.lww.com/RCT/A64). Patients' symptoms were recorded. The tumor wall was considered perceptible if it was greater than 3 mm thick. Vascular invasion was suggested if there was a contiguous filling defect in the vessel extending from the tumor and showed contrast enhancement and similar imaging features to the primary tumor. The pancreatic duct was considered dilated if it was greater than 5 mm in size. The tumors were categorized as homogeneous or heterogeneous and as predominantly cystic, predominantly solid, or mixed in internal architecture. Internal hemorrhage was defined by high-attenuation material present within the tumor at greater than 45 HU. Calcifications were categorized by location within the tumor (central punctate, eccentric, or peripheral punctate). 
Quantitative Analysis
The regions of interest (ROIs) in the tumor and the normal pancreas were documented. The ROIs included the entire solid portion of the tumor and were drawn manually on the noncontrast, arterial, portal-venous, and delayed phases of contrast enhancement. A 2-cm 2 ROI was also placed on normal pancreas upstream from the tumor during all 3 contrast phases. Lymph nodes in the peripancreatic region and in the portahepatis were considered suspicious for metastatic disease if they were greater than 1.0 cm in the short-axis diameter. 25 
Pathologic Analysis
Pathologically aggressive tumor features were defined as a diameter of greater than 5 cm, tumor necrosis, invasion into peripancreatic soft tissue, extension into the adjacent fat, and lymphovascular/perineural invasion (Fig. 1) . 26 Tumors, which had these pathologic features, were considered aggressive, and tumors, which did not have these features, were considered nonaggressive.
Statistical Analysis
Qualitative features were analyzed using contingency tables with Fisher exact test. Hounsfield unit values between tumor groups were compared using Wilcoxon rank-sum test. The tumors were classified as aggressive versus nonaggressive based on pathological analysis. Recursive partitioning analysis (RPA) was performed to identify a cutoff value for predicting invasiveness. Kaplan-Meier analysis was used to assess overall survival. P values of less than 0.05 were considered statistically significant. The RPA analysis and data plotting were carried out using R Version 3.1.1 (R Foundation, Vienna, Austria). Other statistical analyses were performed using SAS Version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Forty patients were included in our analysis. Based on pathology, 15 patients (37.5%) had aggressive tumors and 25 patients (62.5%) did not. The mean (SD) patient age was 30.7 (14.3) years. The mean (SD) tumor size was 5.3 (3.6) cm. There were 35 female and 5 male patients. Three of the 5 male patients had pathologically aggressive tumors. Twelve of the 35 female patients had aggressive tumors based on pathology. Patients were generally symptomatic, presenting with vague abdominal pain, nausea, vomiting, and bloating. Two patients presented with jaundice. None of the patients had elevated cancer antigen 19-9 at presentation. Two patients presented with aggressive features on pathology had metastatic disease to the liver.
Qualitative Analysis
Location (head, body, or tail) did not significantly differ between aggressive and nonaggressive tumors (P = 0.32). Nine of the 19 tumors presenting in the head of the pancreas had aggressive eatures (Figs. 2, 3) . The following morphologic CECT features of the tumors also did not significantly differ between aggressive and nonaggressive tumors, including internal hemorrhage (P = 0.67), calcification (P = 0.71), wall thickness perceptibility (P = 0.67), homogeneity on enhancement (P = 0.67), calcification (P = 0.87), vascular invasion (P = 0.42), margins (P ≥ 0.99), capsule irregularity (P = 0.44), pancreatic ductal dilation (P > 0.99), biliary ductal dilation (P = 0.06), and lymphadenopathy (P = 0.13). The amount of cystic component within the tumor did not significantly differ between aggressiveness groups (P = 0.64). All tumors had low attenuation relative to the pancreatic parenchyma on all phases of contrast enhancement.
Lymphadenopathy was seen in 11 of 40 patients on imaging; however, none of the lymph nodes contained metastases by pathology.
Quantitative Analysis
The HU values of the tumor did not significantly differ between aggressive and nonaggressive tumors when correlated with pathologic diagnosis in the pancreatic parenchymal phase (P = 0.36) or portal venous phase (P = 0.45). However, greater enhancement in the delayed phase of contrast was associated with aggressiveness (P = 0.03; Table 1 ). Based on RPA of 62.5 HU or greater, the accuracy was 73%, sensitivity was 90%, specificity was 65%, positive predictive value was 56%, and negative predictive value was 93%. The prediction of aggressive versus nonaggressive tumors using 62.5 HU or greater had a P value of 0.0026 (Table 2, Fig. 4) .
The tumors, which had aggressive features, had progressive enhancement, whereas the nonaggressive tumors demonstrated washout of contrast (Fig. 5 ). Two patients who had aggressive features on pathology and liver metastases had tumors that showed progressive enhancement.
On last follow-up, 3 patients had died, and the rest were still alive. The survival time of the 3 patients was 6, 13 and 15 months. The Kaplan-Meier curve showed that the 10-year survival of SPNs was more than 90% (Fig. 6 ).
DISCUSSION
Our study suggests 62.5 HU or greater on delayed phase of SPNs correlated with aggressive pathologic features. In addition, SPNs that showed a progressive increase in enhancement had aggressive pathologic features, whereas nonaggressive tumors showed washout of contrast. This imaging finding has not been described in the literature. All SPNs however were lower in attenuation to the pancreatic parenchyma similar to a recently published study. 27 Most of the tumors we encountered were solid with a low incidence of mixed solid-cystic and purely cystic lesions. Previous studies reported mixed cystic tumors and solid-appearing tumors to be more common among SPNs than those with a mostly solid or mostly cystic composition. 28 In addition, studies have suggested that solid tumors have an aggressive pathology than cystic or mixed cystic tumors. 21 However, we found aggressive and nonaggressive pathologic features occurring with nearly equal frequency in solid and cystic lesions. We also found that aggressive and nonaggressive tumors could not be differentiated by the qualitative enhancement characteristics (low, equal, or high in attenuation compared with the pancreatic parenchyma) of their solid component.
Most of the lesions in our study had well-circumscribed margins with imperceptible walls, and these features did not significantly differ between aggressive and nonaggressive disease. Most of the tumors were round or lobulated irrespective of pathologic features. Two aggressive tumors demonstrated capsular irregularity, that is, focal discontinuity of the capsule, which has been suggested as a feature that can be used to diagnose tumor aggressiveness. 29 Yin et al 24 showed a difference in capsular morphologic features such that aggressive tumors had discontinuity of the capsule (P = 0.05) or size of greater than 6 cm (P = 0.02); however, such differences in association with aggression did not reach statistical significance in our study.
Calcification (16/40) and hemorrhage (9/40) within the lesions were not frequently observed in our study. Yin et al 24 stated that presence of amorphous or scattered calcifications and solid composition favor a benign pathology. Another study suggested that the presence of calcification is a behavior of malignancy. 30 Although we also found calcifications and hemorrhage to be more prevalent in benign tumors, the divergence in these features was not significantly associated with aggression.
A study has suggested that SPNs of less than 3 cm in diameter are more likely to be completely solid with a well-circumscribed margin and to have other different imaging characteristics, compared with tumors that are greater than 3 cm. 31 In our study, 7 tumors were 3 cm or greater; one of these was completely cystic, and one had mixed cystic and solid components. Three of these tumors did not have a well-circumscribed margin. None of the tumors that were 3 cm or greater had internal hemorrhage, which is in accordance with the findings of Chae et al. 31, 32 No pancreatic ductal dilation was seen in patients who had tumors of 3 cm or greater (0/7); however, 8 of the 32 tumors of greater than 3 cm did show pancreatic ductal dilation. Ductal dilation has been FIGURE 4. The box plots were overlaid with the actual data points (blue). To avoid overlap of data points with same value, the data points were scattered horizontally (jittered). In the box-and-whisker plot, the ends of the box represent the 25th and 75th quartiles. The line within the box represents the median sample value. The diamond shape represents the mean. The difference between the 25th and 75th quartiles is called the IQR. The lower whisker extends from the lower end of the box to the minimum value that is greater than or equal to the 25th quartile minus 1.5 times the IQR, and the upper whisker extends from the upper end of the box to the maximum value that is less than or equal to the 75th quartile plus 1.5 times the IQR. Del, ROI of the tumor on delayed image; I, invasive; N, noninvasive. Figure 4 can be viewed online in color at www.jcat.org. correlated with recurrence and metastases in SPNs, but we did not see this link in our study. 33 Solid pseudopapillary neoplasms are low in attenuation relative to the pancreatic parenchyma, an imaging finding similar to pancreatic ductal cancer; even though SPNs may present with ductal dilation, they should not be mistaken for pancreatic cancer.
As shown in the literature, SPNs in our study were more commonly seen in females than in males (88% vs 13%). 2, 32 Two female patients with aggressive pathology in our cohort had liver metastases. This finding is in accordance with a study suggesting that patients with aggressive tumor features on pathologic analysis may present with metastatic disease, 34, 35 and these histopathologic findings may warrant close follow-up of patients. 34 One of the female patients with hepatic metastases demonstrating growth into the superior mesenteric and portal vein is alive, and this finding is in concordance with one series that suggested that venous invasion/extension based on imaging findings does not adversely affect the long-term outcome. 36 Our results are similar to those published in the literature 24, [37] [38] [39] showing that the malignant potential (potential to metastasize) of SPNs cannot be determined on the basis of factors such as sex 40 ; age, cystic, solid, or mixed appearance on cross-sectional imaging; or location.
The overall prognosis of SPN is good for both aggressive and nonaggressive tumors. 41 In the presence of extrapancreatic extension, the tumors are resected en bloc, including resection of the portal/superior mesenteric venous confluence if necessary. 42, 43 Even in SPNs with metastases, surgical removal of tumor and metastases is the standard approach owing to the favorable biologic features of these tumors. 10, 34 We did not observe recurrence in our cohort; however, studies have suggested that SPNs with aggressive histopathologic features may recur. 16, 35 Follow-up imaging may be necessary in these patients to detect early recurrence.
In our cohort, despite the presence of large lymph nodes on imaging, patients did not have metastatic adenopathy, as also seen in a study by Tipton et al. 26, 34 Other studies have also alluded that a formal lymphadenectomy, despite the presence of enlarged lymph nodes, may not be necessary. 34, 38, 44, 45 Given the excellent prognosis and difficulty to predict the outcomes of patients with pathologically aggressive tumors, surveillance after surgical resection of the tumor is crucial. 41 There are several limitations to our study. First, it was a retrospective analysis in a single institution and had the limitations inherent to that design. Only patients who have baseline imaging before surgical resection were included in the study. Second, the images were interpreted in consensus; hence, we could not assess the κ statistic. Third, all the images were not obtained on the same 64-detector general electric scanner, and interscanner variability was not taken into account. Fourth, on enhancement using the ROIs, only the HU values of the solid portion of the tumor were assessed, and the HU values of the cystic areas were not recorded.
CONCLUSIONS
Our study suggests that pathologically aggressive SPNs may have HU values of 62.6 or greater of the solid component of the tumor on the delayed phase of contrast and show progressive enhancement. Solid pseudopapillary neoplasms with these aggressive-associated features should be followed up closely, because they may develop metastases or have recurrence based on literature. Further prospective studies would be helpful in confirming our findings of progressive enhancement and correlation with aggressive features.
